Closing on Nov. 17: Investor Calendar + Company Spotlight

INVESTOR NETWORK is the go-to, one-stop site for shareholders, clients and prospective investors



Sector: Pharmaceutical Preparations Region: France

: | New York Stock Exchange: SNY

Sanofi, a global and diversified healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients’ needs. Sanofi has core strengths in healthcare, with 6 growth platforms: emerging markets, vaccines, consumer healthcare, diabetes treatments, innovative products and animal health. Through the acquisition of Genzyme, Sanofi has strongly reinforced its footprint in rare diseases.

Investor Calendar

Oct 31, 2018 2:30 pm | 2018 Third Quarter Earnings

Jul 31, 2018 2:30 pm | Q2 Earnings Call

Jul 31, 2018 8:30 am | Q2 Earnings Call

Apr 27, 2018 8:30 am | Q1 Earnings Call

Feb 7, 2018 8:00 am | Q4 Earnings Call

Latest Media

Warning! Third-party cookies must be enabled to view SlideShare presentations. ×

Having trouble?

We Are Sanofi

Discover testimonies from Sanofi employees from all over the world.

Sanofi video

We Are Sanofi


Olivier Brandicourt, Chief Executive Officer
Olivier Brandicourt has 28 years of global experience in the pharmaceutical industry, most recently as Chairman of the Board of Management of Bayer HealthCare AG and member of the Executive Council of Bayer AG. Previously, Brandicourt held numerous positions of increasing responsibility within major global pharmaceutical groups, such as Parke-Davis/Warner-Lambert and Pfizer. Notably, Brandicourt served as a member of Pfizer’s global Executive Leadership Team from 2010 - 2013. A physician by training, Olivier Brandicourt’s career includes several senior positions in Europe, Canada and the United States. As the head of various key healthcare divisions, he has a broad range of expertise and knowledge of the pharmaceutical industry and has led the launch of numerous new medicines and the completion of strategic acquisitions and integrations. Serge Weinberg, Chairman of the Board of Directors, Sanofi said, “Sanofi undertook a rigorous selection process to identify the right person to lead Sanofi forward at an important time for our company. I am very pleased that Olivier Brandicourt will be the next chief executive officer of Sanofi. Olivier Brandicourt’s strong experience combined with his international profile, deep knowledge of U.S. and emerging healthcare markets, and his capability to unite teams will provide new dynamism to Sanofi’s strategy of diversification and innovation.”
Jerome Contamine, Executive Vice President, Chief Financial Officer
Jérôme Contamine is a Graduate of Ecole Polytechnique (X), France’s most prestigious engineering school, and ENSAE, the national statistics and economics engineering school. He graduated from the elite ENA - Ecole Nationale d’Administration - opting for the French Court of Audit - “Cour des Comptes” in 1984.

News & Analysis